Longboard Pharmaceuticals has completed the enrolment of 52 participants in the Phase Ib/IIa PACIFIC study of LP352 to treat developmental and epileptic encephalopathies (DEEs).

Patients with a broad range of DEEs including SCN2A-related epilepsies, CDKL5 deficiency disorder, Lennox-Gastaut syndrome, and Dravet syndrome are enrolled from 30 study sites in Australia and the US.

The primary goal of the study is to evaluate the tolerability and safety of the centrally acting 5-HT2C receptor superagonist LP352.

Over the treatment period, the trial will also assess change in seizure frequency.

Topline results from the trial are anticipated at the end of this year.

The company intends to use the data obtained from this trial to design the planned Phase III programme for LP352.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

It also anticipates initiating a Phase II multicentre, multiple-dose, open-label extension (OLE) clinical trial to assess long-term safety of LP352.

Patients who complete the PACIFIC study are eligible to participate in this trial.

Longboard Pharmaceuticals chief medical officer Dr Randall Kaye said: “We would like to thank the entire DEE community, including participants, their families and the advocates, as well as the investigators, sites and coordinators for their participation and continued collaboration.

“This achievement brings us one step closer to helping people living with developmental and epileptic encephalopathies.”

DEEs are a group of severe heterogeneous epilepsies characterised by drug resistant seizures and significant delay in development.

The company is also assessing oral, centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, LP659, in multiple neurological diseases.